Recently, the team of Professor Chen Xiang and Professor Yin Mingzhu from the Department of Dermatology of Xiangya Hsopital of Central South University, Hunan Key Laboratory of Skin Cancer and Psoriasis, and Hunan Engineering Research Center of Skin Health and Disease published a research paper titledBET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathwayinTheranostics(IF: 8.579), a top journal in this field. The paper was about a bromodomain and extraterminal domain (BET) inhibitor (NHWD-870) and was featured on the cover of the journal. Postdocs Deng Guangtong and Zeng Furong from Xiangya Hospital are first authors. Professor Chen Xiang and Professor Yin Mingzhu are corresponding authors. Xiangya Hospital is the affiliation of first authors and the first corresponding unit.
In April, the team of Professor Chen Xiang and Professor Yin Mingzhu published inNature Communicationstheir research results that NHWD-870, a self-developed new BET inhibitor, could inhibit the proliferation of cancer cells by suppressing cancer cell-macrophage interaction. The recent study revealed that the BET inhibitor could directly inhibit the expression of secreted phosphoprotein 1 (SPP1), a potential melanoma driver, through NFKB2, thus suppressing melanoma progression. This study provided more theoretical basis for the effective treatment of solid tumors, including melanoma, through suppressing BRD4, an epigenetic reader, and its target, and identified a new target for evaluating clinical efficacy in the phase I clinical trial of NHWD-870 HCl, a Class 1 innovative new drug jointly developed by the team of Professor Chen Xiang and Professor Yin Mingzhu and Ningbo Wenda Pharma Technology Co., Ltd.
The team led by Professor Chen Xiang has long been dedicated to basic research and clinical diagnosis and treatment of skin tumors, and took the lead in establishing the Skin Tumors Research Center of the Chinese Society of Dermatology of the Chinese Medical Association and the Skin Tumors Committee of the Chinese Dermatologist Association. Since 2009, Professor Yin Mingzhu has been mainly engaged in the research related to clinical translation. He has done a lot of pioneering work of theoretical and practical significance in exploring the mechanism of cancer cell-macrophage interaction, identifying new targets for epigenetic therapy for tumors, and developing new drugs. His research results have been widely recognized by his counterparts from all around the world, and provided new strategies and ideas for improving the efficacy of cancer therapy and developing new anticancer drugs.
